Treatment of Tinea in Infants
For tinea capitis in infants, oral systemic antifungal therapy is required, with the specific agent chosen based on the causative organism and the infant's age. Topical therapy alone is insufficient for cure 1.
Treatment Algorithm by Age and Organism
For Infants ≥1 Month Old
First-line therapy depends on the causative dermatophyte:
For Trichophyton species (T. tonsurans, T. violaceum, T. soudanense):
- Terbinafine is more efficacious
- Dose for infants <20 kg: 62.5 mg daily for 2-4 weeks 1
- Shorter treatment duration improves compliance
For Microsporum species (M. canis, M. audouinii):
For Neonates <1 Month Old
This is a challenging scenario with limited data. The evidence shows:
- Fluconazole is preferred by pediatric dermatologists for infants under 2 months 2
- Itraconazole pulse therapy has been successfully used in a 23-day-old newborn at 5 mg/kg/day 3
- Topical therapy alone has achieved cure in select neonatal cases (16-day-old and 24-day-old infants) 4, 5, though this contradicts standard guidelines
Given the lack of robust data in neonates and the guideline emphasis on systemic therapy, I recommend systemic treatment even in this age group when feasible, with fluconazole or itraconazole as the safest options based on available case reports.
Second-Line Therapy
If first-line treatment fails after 2-4 weeks:
- Itraconazole 5 mg/kg/day for 2-4 weeks (or 50-100 mg/day for 4 weeks) 1
- Effective against both Trichophyton and Microsporum species
- Can be given as pulse therapy (1 week on, 2 weeks off) 3, 6
Critical Adjunctive Measures
Beyond medication, these steps are essential:
- Obtain fungal culture before starting treatment when possible, but don't delay therapy if kerion, scaling, lymphadenopathy, or alopecia are present 1
- Add antifungal shampoo (ketoconazole 2%, selenium sulfide 1%, or povidone-iodine) to reduce spore transmission 1
- Screen and treat family members for T. tonsurans infections, as >50% may be affected 1
- Follow-up with repeat mycology until mycological cure is documented, not just clinical improvement 1
- Allow school/nursery attendance once appropriate therapy is started 1
Common Pitfalls to Avoid
Do not use topical therapy alone for tinea capitis—it cannot penetrate the hair shaft adequately 1. The exception is the rare neonate where systemic therapy poses significant risk and close monitoring is possible.
Do not choose terbinafine empirically without knowing the organism—it fails frequently for Microsporum infections because it doesn't reach adequate concentrations in prepubertal children's hair shafts 1.
Do not stop treatment based on clinical improvement alone—continue until mycological clearance is confirmed, as clinical cure does not equal mycological cure 1.
Consider treatment failure causes systematically: non-compliance, poor drug absorption, organism resistance, or reinfection before switching agents 1.
Species-Specific Efficacy Nuance
The evidence strongly emphasizes that treatment choice must be organism-directed 1. Terbinafine achieves 88.5% cure for Trichophyton but significantly lower rates for Microsporum, while griseofulvin shows the opposite pattern 1. This pharmacologic difference stems from terbinafine's inability to be incorporated into hair shafts in prepubertal children and its lack of excretion in sweat/sebum where Microsporum arthroconidia reside 1.